Cargando…
Intermittent administration of atezolizumab with combined carboplatin and etoposide therapy for patients with extensive‑disease small cell lung cancer
To the best of our knowledge, no published reports have examined the significance of additional immune checkpoint inhibitors in treating malignancies, including lung cancer. Therefore, the present study aimed to examine the efficacy and feasibility of adding atezolizumab to carboplatin and etoposide...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9932630/ https://www.ncbi.nlm.nih.gov/pubmed/36817046 http://dx.doi.org/10.3892/ol.2023.13696 |
_version_ | 1784889496071831552 |
---|---|
author | Tsuda, Takeshi Imai, Hisao Nagai, Yoshiaki Umeda, Yukihiro Shiono, Ayako Shiihara, Jun Yamaguchi, Ou Mouri, Atsuto Kaira, Kyoichi Ishizuka, Tamotsu Taniguchi, Hirokazu Kagamu, Hiroshi |
author_facet | Tsuda, Takeshi Imai, Hisao Nagai, Yoshiaki Umeda, Yukihiro Shiono, Ayako Shiihara, Jun Yamaguchi, Ou Mouri, Atsuto Kaira, Kyoichi Ishizuka, Tamotsu Taniguchi, Hirokazu Kagamu, Hiroshi |
author_sort | Tsuda, Takeshi |
collection | PubMed |
description | To the best of our knowledge, no published reports have examined the significance of additional immune checkpoint inhibitors in treating malignancies, including lung cancer. Therefore, the present study aimed to examine the efficacy and feasibility of adding atezolizumab to carboplatin and etoposide combination chemotherapy for small cell lung cancer with extensive disease (ED-SCLC). The present retrospective analysis examined 16 patients with ED-SCLC who received the addition of atezolizumab to carboplatin and etoposide therapy during treatment at four institutions between August 2019 and September 2020. The effectiveness of treatment was evaluated based on tumor response, survival time and adverse events. Within the study cohort, there were 14 males (87.5%) and 2 females (12.5%), with a median age of 73.5 years (range, 62–79 years); 7 patients had a performance status (PS) of 0–1 (43.8%) and 9 had a PS of 2–3 (56.3%). The median follow-up period was 12.1 months. The overall response rate, median progression-free survival time and median overall survival time were 75.0%, 5.3 and 13.0 months, respectively. Regarding the frequency of hematological adverse events, the occurrence of grade ≥3 adverse events was observed, including decreased neutrophil (56.3%), white blood cell (50.0%) and platelet (43.8%) counts, as well as febrile neutropenia (12.5%). Although 1 patient developed grade 3 pneumonitis as a serious adverse event, no treatment-related deaths were observed. Despite the aforementioned hematological toxicities, the addition of atezolizumab to carboplatin and etoposide therapy during treatment demonstrated favorable efficacy and acceptable toxicity in ED-SCLC. Thus, adding atezolizumab to carboplatin and etoposide combination chemotherapy may be a treatment option for ED-SCLC. |
format | Online Article Text |
id | pubmed-9932630 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | D.A. Spandidos |
record_format | MEDLINE/PubMed |
spelling | pubmed-99326302023-02-17 Intermittent administration of atezolizumab with combined carboplatin and etoposide therapy for patients with extensive‑disease small cell lung cancer Tsuda, Takeshi Imai, Hisao Nagai, Yoshiaki Umeda, Yukihiro Shiono, Ayako Shiihara, Jun Yamaguchi, Ou Mouri, Atsuto Kaira, Kyoichi Ishizuka, Tamotsu Taniguchi, Hirokazu Kagamu, Hiroshi Oncol Lett Articles To the best of our knowledge, no published reports have examined the significance of additional immune checkpoint inhibitors in treating malignancies, including lung cancer. Therefore, the present study aimed to examine the efficacy and feasibility of adding atezolizumab to carboplatin and etoposide combination chemotherapy for small cell lung cancer with extensive disease (ED-SCLC). The present retrospective analysis examined 16 patients with ED-SCLC who received the addition of atezolizumab to carboplatin and etoposide therapy during treatment at four institutions between August 2019 and September 2020. The effectiveness of treatment was evaluated based on tumor response, survival time and adverse events. Within the study cohort, there were 14 males (87.5%) and 2 females (12.5%), with a median age of 73.5 years (range, 62–79 years); 7 patients had a performance status (PS) of 0–1 (43.8%) and 9 had a PS of 2–3 (56.3%). The median follow-up period was 12.1 months. The overall response rate, median progression-free survival time and median overall survival time were 75.0%, 5.3 and 13.0 months, respectively. Regarding the frequency of hematological adverse events, the occurrence of grade ≥3 adverse events was observed, including decreased neutrophil (56.3%), white blood cell (50.0%) and platelet (43.8%) counts, as well as febrile neutropenia (12.5%). Although 1 patient developed grade 3 pneumonitis as a serious adverse event, no treatment-related deaths were observed. Despite the aforementioned hematological toxicities, the addition of atezolizumab to carboplatin and etoposide therapy during treatment demonstrated favorable efficacy and acceptable toxicity in ED-SCLC. Thus, adding atezolizumab to carboplatin and etoposide combination chemotherapy may be a treatment option for ED-SCLC. D.A. Spandidos 2023-02-02 /pmc/articles/PMC9932630/ /pubmed/36817046 http://dx.doi.org/10.3892/ol.2023.13696 Text en Copyright: © Tsuda et al. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made. |
spellingShingle | Articles Tsuda, Takeshi Imai, Hisao Nagai, Yoshiaki Umeda, Yukihiro Shiono, Ayako Shiihara, Jun Yamaguchi, Ou Mouri, Atsuto Kaira, Kyoichi Ishizuka, Tamotsu Taniguchi, Hirokazu Kagamu, Hiroshi Intermittent administration of atezolizumab with combined carboplatin and etoposide therapy for patients with extensive‑disease small cell lung cancer |
title | Intermittent administration of atezolizumab with combined carboplatin and etoposide therapy for patients with extensive‑disease small cell lung cancer |
title_full | Intermittent administration of atezolizumab with combined carboplatin and etoposide therapy for patients with extensive‑disease small cell lung cancer |
title_fullStr | Intermittent administration of atezolizumab with combined carboplatin and etoposide therapy for patients with extensive‑disease small cell lung cancer |
title_full_unstemmed | Intermittent administration of atezolizumab with combined carboplatin and etoposide therapy for patients with extensive‑disease small cell lung cancer |
title_short | Intermittent administration of atezolizumab with combined carboplatin and etoposide therapy for patients with extensive‑disease small cell lung cancer |
title_sort | intermittent administration of atezolizumab with combined carboplatin and etoposide therapy for patients with extensive‑disease small cell lung cancer |
topic | Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9932630/ https://www.ncbi.nlm.nih.gov/pubmed/36817046 http://dx.doi.org/10.3892/ol.2023.13696 |
work_keys_str_mv | AT tsudatakeshi intermittentadministrationofatezolizumabwithcombinedcarboplatinandetoposidetherapyforpatientswithextensivediseasesmallcelllungcancer AT imaihisao intermittentadministrationofatezolizumabwithcombinedcarboplatinandetoposidetherapyforpatientswithextensivediseasesmallcelllungcancer AT nagaiyoshiaki intermittentadministrationofatezolizumabwithcombinedcarboplatinandetoposidetherapyforpatientswithextensivediseasesmallcelllungcancer AT umedayukihiro intermittentadministrationofatezolizumabwithcombinedcarboplatinandetoposidetherapyforpatientswithextensivediseasesmallcelllungcancer AT shionoayako intermittentadministrationofatezolizumabwithcombinedcarboplatinandetoposidetherapyforpatientswithextensivediseasesmallcelllungcancer AT shiiharajun intermittentadministrationofatezolizumabwithcombinedcarboplatinandetoposidetherapyforpatientswithextensivediseasesmallcelllungcancer AT yamaguchiou intermittentadministrationofatezolizumabwithcombinedcarboplatinandetoposidetherapyforpatientswithextensivediseasesmallcelllungcancer AT mouriatsuto intermittentadministrationofatezolizumabwithcombinedcarboplatinandetoposidetherapyforpatientswithextensivediseasesmallcelllungcancer AT kairakyoichi intermittentadministrationofatezolizumabwithcombinedcarboplatinandetoposidetherapyforpatientswithextensivediseasesmallcelllungcancer AT ishizukatamotsu intermittentadministrationofatezolizumabwithcombinedcarboplatinandetoposidetherapyforpatientswithextensivediseasesmallcelllungcancer AT taniguchihirokazu intermittentadministrationofatezolizumabwithcombinedcarboplatinandetoposidetherapyforpatientswithextensivediseasesmallcelllungcancer AT kagamuhiroshi intermittentadministrationofatezolizumabwithcombinedcarboplatinandetoposidetherapyforpatientswithextensivediseasesmallcelllungcancer |